{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"}],"units":"Participants"}],"description":"Defined as the dose at which \\>= 2 patients experience dose-limiting toxicity, graded in severity according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0","groups":[{"description":"CONCURRENT PHASE: Patients undergo fractionated stereotactic radiosurgery QD every weekday for 10 days and receive alisertib PO BID concurrently with radiation therapy for 10 days.\n\nMAINTENANCE PHASE: Patients receive alisertib PO BID on days 1-7. Treatment repeats every 21 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.\n\nHyperfractionated radiation therapy: Undergo hyperfractionated radiation therapy\n\nStereotactic radiosurgery: Undergo stereotactic radiosurgery\n\nAlisertib: Given PO\n\nQuality-of-life assessment: Ancillary studies","id":"OG000","title":"Alisertib, Fractionated Stereotactic Radiosurgery"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 30 days after completion of radiation therapy","title":"Maximum Tolerated Dose (MTD) of Alisertib","type":"PRIMARY","unitOfMeasure":"mg dose of Alisertib"}